53 related articles for article (PubMed ID: 38468814)
1. Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis
Wu M; Jin MM; Cao XH; Zhao L; Li YH
Curr Cancer Drug Targets; 2024; 24(4):445-454. PubMed ID: 37644752
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer.
Liu B; Peng Y; Su Y; Diao C; Qian J; Zhan X; Cheng R
Anticancer Drugs; 2024 Jun; ():. PubMed ID: 38820067
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway.
Wang L; Xu L; Han S; Zhu X
Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
[TBL] [Abstract][Full Text] [Related]
4. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
5. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
7. Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.
Zhu C; Jiang X; Xiao H; Guan J
Biochem Genet; 2022 Dec; 60(6):2434-2454. PubMed ID: 35460386
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis.
Lei T; Xu T; Zhang N; Zou X; Kong Z; Wei C; Wang Z
Pharmacol Res; 2023 Feb; 188():106668. PubMed ID: 36681369
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1.
Deng Y; Ma G; Vallega KA; Wang D; Wang M; Wang C; Wang S; Ramalingam SS; Sun SY
Cancer Gene Ther; 2022 Nov; 29(11):1558-1569. PubMed ID: 35449204
[TBL] [Abstract][Full Text] [Related]
12. CircACC1 Promotes NSCLC Proliferation
Zhu B; Ke L; Li P; Wang X; Yang L; Bai M; Chen M
Front Genet; 2021; 12():798587. PubMed ID: 35069696
[TBL] [Abstract][Full Text] [Related]
13. Cytokines screening identifies MIG (CXCL9) for postoperative recurrence prediction in operated non-small cell lung cancer patients.
Zhang N; Tan Q; Tao D; Song Y; Song W; Wang J; Ma L; Wu D; Feng Y; Yao J; Han X; Shi Y
Cytokine; 2022 Jan; 149():155759. PubMed ID: 34775109
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
